Medicxi Ventures Management Jersey Ltd Has $85.60 Million Position in NewAmsterdam Pharma Company N.V. $NAMS

Medicxi Ventures Management Jersey Ltd lowered its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 6.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,674,182 shares of the company’s stock after selling 195,383 shares during the quarter. NewAmsterdam Pharma makes up 8.7% of Medicxi Ventures Management Jersey Ltd’s portfolio, making the stock its 2nd biggest holding. Medicxi Ventures Management Jersey Ltd owned approximately 2.33% of NewAmsterdam Pharma worth $85,601,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NAMS. Farther Finance Advisors LLC boosted its stake in NewAmsterdam Pharma by 4,425.0% in the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock worth $25,000 after purchasing an additional 708 shares during the period. Wells Fargo & Company MN grew its holdings in NewAmsterdam Pharma by 50.0% during the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock valued at $32,000 after buying an additional 300 shares in the last quarter. Navalign LLC purchased a new stake in NewAmsterdam Pharma during the 4th quarter valued at approximately $46,000. AdvisorNet Financial Inc bought a new stake in shares of NewAmsterdam Pharma during the first quarter valued at approximately $82,000. Finally, Empowered Funds LLC bought a new stake in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $85,000. Institutional investors own 89.89% of the company’s stock.

Insider Activity

In other news, CAO Louise Frederika Kooij sold 40,000 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $30.20, for a total transaction of $1,208,000.00. Following the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $735,460.60. This represents a 62.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 12.74% of the company’s stock.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $33.24 on Friday. The stock has a market capitalization of $3.89 billion, a PE ratio of -18.57 and a beta of 0.07. The company’s fifty day moving average is $32.80 and its 200 day moving average is $33.14. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $17.97 and a fifty-two week high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. The business had revenue of $3.04 million for the quarter. As a group, research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.78 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Truist Financial began coverage on shares of NewAmsterdam Pharma in a report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.60.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.